Ditchcarbon
  • Contact
  1. Organizations
  2. GRAIL, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 8 months ago

GRAIL, Inc. Sustainability Profile

Company website

GRAIL, Inc., a pioneering company in the field of early cancer detection, is headquartered in the United States. Founded in 2016, GRAIL has rapidly established itself as a leader in the biotechnology industry, focusing on innovative blood tests that aim to identify multiple types of cancer at their earliest stages. With a commitment to transforming cancer care, GRAIL's flagship product, Galleri™, utilises advanced genomic sequencing technology to detect cancer signals in the bloodstream, setting it apart from traditional screening methods. The company has achieved significant milestones, including partnerships with major healthcare providers and research institutions, enhancing its market position. GRAIL continues to push the boundaries of cancer diagnostics, striving to improve patient outcomes and revolutionise the way cancer is detected and treated.

DitchCarbon Score

How does GRAIL, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

28

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

GRAIL, Inc.'s score of 28 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.

48%

Let us know if this data was useful to you

GRAIL, Inc.'s reported carbon emissions

GRAIL, Inc., headquartered in the United States, has made significant commitments towards reducing its carbon emissions, although specific emissions data is currently unavailable. The company is committed to achieving net-zero emissions across all scopes by 2050, with interim targets set for 2025. This commitment is aligned with the Science Based Targets initiative (SBTi), which underscores GRAIL's dedication to climate action within the pharmaceuticals, biotechnology, and life sciences sector. As of now, GRAIL has not reported any absolute emissions figures (in kg CO2e) or specific reduction achievements. However, their long-term strategy reflects a proactive approach to sustainability and climate responsibility. The absence of emissions data suggests that GRAIL is in the early stages of its emissions tracking and reporting journey, but their commitment to net-zero emissions indicates a forward-thinking strategy aimed at mitigating climate impact.

How Carbon Intensive is GRAIL, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. GRAIL, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is GRAIL, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for GRAIL, Inc. is in US, which has a low grid carbon intensity relative to other regions.

GRAIL, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

GRAIL, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare GRAIL, Inc.'s Emissions with Industry Peers

Personal Genome Diagnostics Inc.

US
•
Research and development services (73)
Updated 14 days ago

Neogenomics

US
•
Other business services (74)
Updated 14 days ago

Biodesix, Inc.

US
•
Other business services (74)
Updated 14 days ago

Labcorp Drug Development Inc.

US
•
Research and development services (73)
Updated 2 months ago

Invitae Corporation

US
•
Other business services (74)
Updated 14 days ago

GeneDx Holdings Corp.

US
•
Other business services (74)
Updated 14 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251114.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
AWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy